Data / Form D filings / CALOSYN PHARMA, INC.
CALOSYN PHARMA, INC.: Form D filings
CALOSYN PHARMA, INC., a biotechnology company in Shreveport, LA, filed 4 Form D notices with the SEC between 2009 and 2024. The latest, on March 7, 2024, reports $750,000 sold of a $2 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2031 Kings Highway, Shreveport, LA, 71103
- Phone
- 13182139240
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1429819
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 7, 2024 | New notice | $2,000,000 | $750,000 | $1,250,000 | 7 | Dec 22, 2022 | sec.gov |
| Feb 29, 2012 | New notice | $2,100,000 | $309,685 | $1,790,315 | 3 | Feb 15, 2012 | sec.gov |
| Apr 13, 2010 | Amendment | $3,265,653 | $1,863,392 | $1,402,261 | 5 | Mar 30, 2009 | sec.gov |
| Apr 13, 2009 | New notice | $400,000 | $400,000 | 5 | Mar 30, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Joseph P. Lovett | Director | |
| Richard R. Babb | Executive Officer, Director | |
| David P. Waddell | Director | |
| Ross P. Barrett | Executive Officer, Director | |
| William R. Grimes | Executive Officer, Director |
Other biotechnology companies in Louisiana that filed recently
- 28bio, Inc. $8.5 million · Oct 29, 2026
- Therapeutic Neuromodulation Systems LLC $1.7 million · Sep 21, 2026
- QUICKTAKE HEALTH CO $2.1 million · Aug 6, 2026
Every Form D from the week of Mar 4, 2024 · All recent filings in Louisiana · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what CALOSYN PHARMA, INC. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.